Rossier Bernard C
Department of Pharmacology, University of Lausanne, Lausanne, Switzerland.
Proc Am Thorac Soc. 2004;1(1):4-9. doi: 10.1513/pats.2306007.
The epithelial sodium channel (ENaC) was cloned just 10 years ago. Since that time, the study of human monogenic diseases (pseudohypoaldosteronism type 1 [PHA-1] and Liddle syndrome), as well as mouse models mimicking salt-losing syndromes (PHA-1) or salt-sensitive hypertension (Liddle syndrome), have greatly contributed to our understanding of the function of ENaC in vivo. In this brief review, I will first discuss ENaC as a limiting factor in the control of ionic composition of the extracellular fluid and then, more specifically, the activation of ENaC by membrane-bound serine proteases. Recent in vitro and in vivo experiments indicate that membrane-bound serine proteases (channel activating proteases [CAP-1, -2, or-3]) may be of critical importance in the activation of ENaC in different organs, such as the kidney, the lung or the cochlea.
上皮钠通道(ENaC)在仅仅10年前才被克隆出来。从那时起,对人类单基因疾病(1型假性醛固酮增多症[PHA - 1]和利德尔综合征)以及模拟失盐综合征(PHA - 1)或盐敏感性高血压(利德尔综合征)的小鼠模型的研究,极大地促进了我们对ENaC在体内功能的理解。在这篇简短的综述中,我将首先讨论ENaC作为细胞外液离子组成控制中的一个限制因素,然后更具体地讨论膜结合丝氨酸蛋白酶对ENaC的激活作用。最近的体外和体内实验表明,膜结合丝氨酸蛋白酶(通道激活蛋白酶[CAP - 1、-2或-3])可能在不同器官(如肾脏、肺或耳蜗)中ENaC的激活中起关键作用。